newsfilter
← Latest News
GlobeNewswire·

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  • FDA approved NRx's first drug, preservative-free ketamine, ahead of the November 10, 2026 GDUFA goal date, marking the first FDA approval of a blow-fill-seal vial with a luer-lock connection.
  • Commercial launch began the week of November 9, 2026, with a 17-person sales force targeting hospitals & group purchasing organizations, with the first order received & shipments scheduled for no later than January 2027.
  • The company estimates the initial US market for preservative-free ketamine at $400 million, growing at 15% annually, with plans to add approved sterile products to potentially double this opportunity in 2027.
  • NRx signed a collaboration with Yale University & PCORI to sponsor a five-year study comparing IV ketamine with intranasal S-ketamine to support the Accelerated Approval pathway for NRX-100.
  • The company aims to submit a rolling New Drug Application for NRX-100 by the end of 2026 based on the Yale collaboration.
  • NRx announced NRX-200, a subcutaneous ketamine formulation using an FDA-approved cyclodextrin vehicle, with pharmacokinetic testing starting in early 2027 & a first-in-human trial targeted for September 2027.
  • DARPA awarded NRx Defense Systems an $11.25 million prime contract in October 2026 to lead the Phase 3 SPARC-TMS trial of NRX-101, with the first two invoices approved for payment in Q4 2026.
  • HOPE Therapeutics operates six locations in Florida treating patients with robotic, neuronavigated TMS in partnership with Zeta Surgical.
  • GeNeuro plans to initiate clinical trials for ALS & schizophrenia in the second half of 2027 with support from US, French, & Swiss governments.
  • The company ended Q3 2026 with $19.8 million in cash & cash equivalents & no convertible debt.
  • Net patient service revenue for Q3 2026 was $1.2 million, compared to $0.2 million in Q3 2025, driven by growth at HOPE Therapeutics clinics.
  • Net loss for Q3 2026 was $2.2 million ($0.05 per share), a significant reduction from the $5.9 million loss in the same period in 2025.
  • Selling, general & administrative expenses increased to $6.6 million in Q3 2026 from $2.8 million in Q3 2025 due to preparation for the commercial launch.
  • The blow-fill-seal packaging reduces cost of goods to approximately $0.75 per unit compared to $3.25 for glass vials, while eliminating needle-related sharps waste.
  • NRx will host a conference call & webcast on November 17, 2026, at 8:00 a.m. ET to discuss these results.
Company
NRx Pharmaceuticals Inc
Keywords
Nasdaq:NRXP, NRx Pharmaceuticals Inc